Giannis Mountzios, Director of 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared on X:
“Ιn approximately 6% of SCLC cases, CDK4/6 inhibitors offer a new therapeutic opportunity”
Title: Retinoblastoma-Proficient Small Cell Lung Cancer: A Novel Entity With Therapeutic Vulnerability?
Authors: Afshin Dowlati, Reza Ferdousi, Abhishek Ajay, Cammie Brewster, Brandon J. Grubb, Angelina Golya, Omid Savari, Minh Lam, Gary M. Wildey.
Read the full article.
You might be interested in:
TREASURE Trial Raises Safety Concerns for Thoracic Radiotherapy With Atezolizumab in ES-SCLC
